

**Drug Utilization Review Board Meeting
Minutes
February 19, 2014**

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members Present:

Lester Labus, MD., Chairman
Ernest Miller, DO
Pat Regan, PharmD
Chris Terpening, PharmD, PhD
KC Lovin, PA-C
C.K. Babcock, PharmD
Scott Brown, RPh (via phone)
Mary Nemeth-Pyles, MSN, RN, CS
John Vanin, MD
Myra Chiang, MD
Kerry Stitzinger, RPh
David Elliott, PharmD

Members Absent:

Greenbrier Almond, MD

DHHR/BMS Staff Present:

Vicki Cunningham, RPh, DUR Coordinator
Brian Thompson, PharmD
Bill Hopkins, Pharmacy Operations Manager
Doug Sorvig, Administrative Assistant

Contract Staff:

Steve Small, M.S., RPh, Rational Drug Therapy Program
Eric Sears, RPh, Molina Medicaid Solutions
Larry Dent, PharmD, Xerox State Healthcare

- I. **Introductions-** Dr. Labus welcomed everyone to the Board meeting.
- II. **Approval of the November 20, 2013 Minutes-** A motion was made to accept the minutes of the November 20, 2013, DUR Board meeting. The motion was seconded and passed.
- III. **Old Business-**
 - A. Dr. Labus, MD., Chairman suggested moving the candidate's election for the Vice-Chairmen to the May meeting. Ballots will be included in the packets.

- B. **Stimulant Utilization Data** - Dr. Labus, MD., Chairman, gave an overview of report on stimulant prescribing for children for children up to six (6) years of age. The information provided listed prescribers, specialties, number of patients, and the number and combinations of stimulant prescriptions for these children. The report was collected after review of the data.

IV. **New Business**

- A. Brenda Stapleton, ParaPro, spoke on behalf of Natroba.
- B. Dr. Khan, Pulmonologist, spoke on behalf of the TobiPodhaler. Some discussion ensued regarding prior authorization criteria, but the no changes were made by the Board.
- C. The Board discussed a recommendation to change the prior authorization criteria for the Cytokine and CAM antagonist class to the following:
Ninety day trials of two of the anti-TNF agents are required before a non-preferred agent will be approved. The recommendation was approved by the Board along with the motion made to approve the changes made to the April 1, 2014 Preferred Drug List
- D. Updates to the PDL from the January 29, 2014 Pharmaceutical and Therapeutics Committee Meeting
The Board approved recommendations to the prior authorization criteria as presented.
See Attachment A
- E. The Board discussed coverage of pseudoephedrine and reviewed a report on the amount reimbursed for by the Medicaid program from July 1, 2013 through December 31, 2013. There were 37 members who had prescriptions filled and 43 prescriptions. Ms. Cunningham stated that a limit of twelve (12) tablets per month had been set by the Bureau and asked for approval of that amount. The Board approved the limit added. The Board asked for a report on the cost of covering tamper-proof products only. The information will be provided for the May meeting.

V. **Reports**

A. Xerox State Healthcare – Larry Dent, PharmD, BCPS gave an overview of RetroDUR activities with slides that included;

1. Recent Retrospective DUR activities;
 - Overutilization of Antibiotics
 - Preferred Proton Pump Inhibitors for 2014
 - 2014 PDL Update Newsletter
 - GI Disorders
2. Intervention Outcomes

- Preferred Statins
- Chronic Anxiety

See Attachment B

B. Molina Fourth Quarter Report -2013

Eric Sears, RPh gave an overview of the Molina 2013 Fourth Quarter Report. The presentation included a review of the Quarterly Overall Summary Report.

- C. **Rational Drug Therapy Program** - Steve Small gave a slide presentation overview of the program activities for the fourth quarter. The presentation included November and December 2013 and January 2014 program summaries, edit overrides and prior authorizations. See Attachment C

VI. **OTHER BUSINESS- OPEN TO THE FLOOR –**

Discussion was brought to the floor with questions regarding prior authorization criteria of the GLP-1 class and whether it should be made similar to the DPP-4 class. The Board asked for a report on the cost of making this change.

VII. **NEXT MEETING AND ADJOURNMENT –**

A motion was made and seconded to adjourn the meeting. All were in favor. The meeting was concluded at 5:24 pm. The next meeting will be held on May 21, Wednesday from 4:00 -6:00 pm at the West Virginia Department of Health and Human Resources Building, 350 Capitol Street, Charleston, West Virginia.